Research programme: non-nucleoside hepatitis C virus NS5B polymerase inhibitors - Genelabs/Novartis

Drug Profile

Research programme: non-nucleoside hepatitis C virus NS5B polymerase inhibitors - Genelabs/Novartis

Alternative Names: GL 49174; GL 59728; GL 60667

Latest Information Update: 13 Jul 2010

Price : $50

At a glance

  • Originator Genelabs Technologies
  • Developer Genelabs Technologies; Novartis
  • Class Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 13 Jul 2010 Discontinued - Preclinical for Hepatitis C in USA (unspecified route)
  • 07 Jan 2009 Genelabs Technologies has been acquired by GlaxoSmithKline
  • 04 Nov 2008 Pharmacodynamics data from a preclinical trial of GL 60667 in Hepatitis C presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top